TLPH

Talphera Inc

0.55

-0.01-1.06%

Opening12:18 08/27 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE0.5553/0.5553

TODAY RANGE0.5200-0.5708

VOL101.59K

MARKET CAP11.28M

52 WEEK RANGE0.3800-1.190

AVG VOL (3M)1.38M

% TURNOVER0.50%

TURNOVER--

P/E (TTM)-1.3773

% RANGE9.15%

EPS(TTM)-0.3989

P/E(FORWARD)-1.2486

P/B1.701

BVPS0.3229

DIVIDEND--

P/S14.31

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP10.98M

SHARES OUTSTANDING20.52M

NEXT EARNINGS11/04-11/10

FREE FLOAT19.99M

LOT SIZE1

EX-DATE10/26/2022

News

Press Releases

Financial Reports

Profile

TipRanks·1d ago
Maxim Group Remains a Buy on Talphera (TLPH)
TipRanks·2d ago
Talphera enrolls 17 patients in 70-patient pivotal NEPHRO CRRT clinical trial
Reuters·2d ago
Talphera Inc. Achieves 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal Trial, On Track for Year-End Completion
Reuters·2d ago
TALPHERA ANNOUNCES ACHIEVEMENT OF 17 PATIENT ENROLLMENT MILESTONE IN NEPHRO CRRT PIVOTAL TRIAL
Reuters·2d ago
TALPHERA INC: ON TRACK FOR PLANNED STUDY COMPLETION BY THE END OF 2025
TipRanks·08/16 14:05
Positive Outlook for Talphera: Buy Rating Backed by Promising Niyad Trial Progress and Strong Financial Position
TipRanks·08/15 04:07
Talphera Reports Q2 2025 Financial Results and Study Progress
Seeking Alpha·08/15 01:11
Talphera outlines accelerated NEPHRO enrollment and lowers 2025 cash operating expense guidance amid protocol shift
TipRanks·08/14 20:16
Talphera lowers 2025 cash operating expense view to $16M-$17M from $17M-$19M
Seeking Alpha·08/14 20:06
Talphera GAAP EPS of -$0.10 beats by $0.03
Reuters·08/14 20:05
Talphera Inc. Reports Q2 2025 Financial Results; Cash Operating Expenses Guidance Reduced to $16-$17 Million from $17-$19 Million
Reuters·08/14 20:05
TALPHERA ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Dow Jones·08/14 20:05
Press Release: Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Seeking Alpha·08/14 14:00
Here are the major earnings after the close Thursday
Seeking Alpha·08/13 21:35
Talphera Q2 2025 Earnings Preview

Same Industry

Name/Symbol

Change%

Price

McKesson

MCK

+0.66%

685.03

Biogen Inc

BIIB

+0.14%

136.91

Amgen Inc

AMGN

-0.77%

287.35

Shire

SHPG

0.00%

179.20

Bristol-Myers Squibb Company Celegne Contingent Value Rights

CELG-RT

+7.48%

0.0388

Lilly Eli & Co

LLY

+0.51%

739.78

Celgene

CELG

0.00%

108.24

Therapeuticsmd Inc

TXMD

+0.80%

1.13

Johnson & Johnson

JNJ

+0.37%

177.14

Abbvie Inc

ABBV

+0.35%

209.09

Zoetis Inc

ZTS

+0.16%

155.04

Gilead Sciences Inc

GILD

-0.54%

114.13

Novo-Nordisk A/S

NVO

+1.67%

56.27

Bristol-Myers Squibb Co

BMY

+0.64%

47.51

Alexion Pharms

ALXN

0.00%

182.50

Pfizer

PFE

+0.64%

25.08

Sanofi FR

SNY

-0.12%

50.24

Sanofi FR

GCVRZ

0.00%

0.8711

Novartis

NVS

+0.26%

126.97

Dr Reddys Labs

RDY

-0.16%

14.19

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.